Navigation Links
CHI's Molecular Medicine Tri-Conference Keynote John Crowley Inspires Feature Film Starring Harrison Ford

John Crowley, a featured Keynote at this year's Molecular Medicine Tri-Conference, is the inspiration for a new film which will find its way onto the big screen January 22.

Needham, Mass. (PRWEB) November 11, 2009 -- Cambridge Healthtech Institute's (CHI) flagship event, the Molecular Medicine Tri-Conference (February 3-5, 2010) will feature inspirational Keynote John F. Crowley, Founder, Novazyme Pharmaceuticals, Inc.

Mr. Crowley, a Harvard educated businessman, created and built a pharmaceutical company devoted entirely to finding a cure for Pompe disease. He will detail his journey through the labyrinth of scientific and business fronts, which lead up to a first-round clinical trial.

In 1998, two of John Crowley's three children were diagnosed with Pompe disease, a rare and fatal neuromuscular disorder that affects only several thousand children worldwide. After his children were given months to live, and being told there was nothing to be done, John began his incredible journey to find a cure for this fatal disease.

Originally dismissed by virtually all in the biotechnology industry as having no chance of success, Novazyme quickly grew to a 100-person company. Crowley, as CEO of Novazyme, commuted weekly from his home in Princeton, NJ, to Oklahoma City. He raised over $27 million in venture capital on Wall Street for Novazyme in less than a year. Within 18 months of his helping Dr. Canfield to start Novazyme, he agreed for Novazyme to be acquired by Genzyme Corporation, the world's third largest biotechnology company, for a price of $225 million, one of the largest amounts ever paid for a pre-clinical drug development company in biotechnology history.

John Crowley's remarkable story will be released in a film starring Harrison Ford and Brendan Fraiser in January 2010, Extraordinary Measures. An uplifting, inspirational drama, it is based on a Wall Street Journal article and subsequent book, The Cure, by Pulitzer Prize-winning writer Geeta Anand. Entitled Crowley, the film chronicles this story of a man who defied conventional wisdom and great odds, and risked his family's future to pursue a cure for his children's life-threatening disease. For more information visit

The Molecular Medicine Tri-Conference Keynote "When Drug Research is Personal", will be held at the Moscone Convention Center in San Francisco, California.

About Molecular Medicine Tri-Conference
Molecular Medicine Tri-Conference -- the flagship event of CHI - has built this year's event around 6 scientific channels, encompassing 11 conferences, providing attendees more learning opportunities than ever before. Featured channels include diagnostics, chemistry, informatics, biologics, cancer and executive. We're looking to provide attendees a more in depth experience into each of these six areas of research and development. As the need for better information, new technologies, improved strategies and competitive intelligence becomes ever more acute, this event provides compelling research insight into the future of molecular medicine. In 2010, we expect close to 3,000 attendees, 1200 participating companies, 150 exhibitors, 100 posters, and representatives from over 38 countries.

About Cambridge Healthtech Institute

Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI's portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech's Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.

Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.

Press Inquiries Please Contact:
Tracey Fielding
(781) 972-5429


Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Combination Products Executive Forum to be Hosted by CHI's Pharmaceutical Strategy Series
2. News from the November/December Issue of Molecular Medicine
3. National Jewish Health Developing a Molecular Roadmap for Chronic Lung Diseases
4. bioTheranostics Announces Commercial Agreement With Lab21 to Market THEROS CancerTYPE ID(R) Molecular Cancer Classifier in United Kingdom, Ireland and Middle East Countries
5. Arcxis Biotechnologies Announces Release of First Commercial Product for Molecular Analysis
6. Meeting highlights the role of molecular imaging biomarkers in clinical research and therapeutics
7. Molecular imaging holds promise for early intervention in common uterine cancer
8. Reportlinker Adds Whos Doing What in Molecular Diagnostics? - Kalorama / Emmes Survey of US Laboratories Report
9. Reportlinker Adds H1N1 (Swine Influenza) Market Assessment (Latest Data, Company Profiles, Implications for Immunoassays and Molecular Assays) Report
10. News from the Latest Issue of Molecular Medicine
11. Inner workings of molecular thermostat point to pathways to fight diabetes, obesity
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... The Multiple System Atrophy Coalition has announced ... Multiple System Atrophy (MSA) research, timed today to coincide with Giving Tuesday 2015, a ... including their ability to work and be productive, to do simple daily activities like ...
(Date:12/1/2015)... ... December 02, 2015 , ... ClinicoEconomics and Outcomes Research ... of treatment for osteoporosis ”. , As corresponding author Dr Ankita Modi says ... with osteoporosis. Based on a large US managed care database, women aged 55 ...
(Date:12/1/2015)... ... December 01, 2015 , ... According to an ... has filed a discrimination claim against the U.S. Department of Health and Human Services, ... Care Act (ACA) plans are breaking the clause in the law prohibiting the denial ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Paul Vitenas, one of the ... named by MedEsthetics magazine as the Best Single Physician Practice in the nation. Dr. ... elite aesthetic physicians honored by the industry publication. , Dr. Vitenas said he ...
(Date:12/1/2015)... York, NY (PRWEB) , ... December 01, 2015 ... ... epidemic in the 1980s we have seen vast improvements in scientific research and ... made significant strides, providing increased hope and relief to those affected by HIV/AIDS. ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 2015   MabVax Therapeutics Holdings, Inc . (OTCQB: ... has filed an Investigational New Drug Application (IND) with ... Company,s lead fully human antibody product HuMab 5B1 as ... to initiate the Phase I clinical trial early in ... The planned Phase I trial will evaluate the ...
(Date:12/1/2015)... FRANCISCO , Dec. 1, 2015  InCarda Therapeutics, ... development and commercialization of therapies for cardiovascular conditions via ... a subsidiary business in Australia . ... trial in Australia in the ... leading investigators and medical centers in Adelaide ...
(Date:12/1/2015)... , Dec. 1, 2015  The migration ... to develop shared care plans that help patients ... care plans will be digitally enabled, incorporate care ... needs and desires. They will also allow all ... patient,s health journey is optimal. That is the ...
Breaking Medicine Technology: